A Randomized, Open-Label, Parallel Group, Drug-drug Interaction Study to Evaluate the Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adult Subjects
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Erdafitinib (Primary) ; Fluconazole; Itraconazole
- Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 31 Oct 2019 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 10 Oct 2019 Results of a cross-study analysis of total 7 studies(NCT01703481,NCT02218073,NCT02231489,EuDRACT-2015-001583-19,NCT02692677,NCT03066687and NCT03135106) published in the Journal of Clinical Pharmacology
- 20 Sep 2017 Status changed from recruiting to completed.